June 30, 2026

AI Tool Finds More Long COVID Cases Than Codes

Nearly 90% of patients who met algorithmic criteria for postacute sequelae of SARS-CoV-2 infection had at least 1 chronic or potentially chronic condition requiring ongoing clinical management.

Conexiant

June 11, 2026

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Conexiant

June 04, 2026

Achieving Long-Term Success in Recurrent Rhinophyma

Case report describes recurrence-free outcomes at 18 months following treatment for triple-recurrent disease.

Conexiant

May 27, 2026

Biologics Commonly Used in Cutaneous Crohn's Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn's disease.

Conexiant

May 27, 2026

Biologics Commonly Used in Cutaneous Crohn Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn disease.

Conexiant

May 20, 2026

Ivarmacitinib Eased Refractory PCA: Case Report

Off-label ivarmacitinib rapidly relieved pruritus and improved skin lesions in a patient with refractory primary cutaneous amyloidosis, according to a case report.

Conexiant

May 13, 2026

Medical Oddities: Ancient Practice Calms Modern BP

Ancient workouts, anxious ears, tea gains, limb regrowth, and furry tongues collide.

Conexiant

May 07, 2026

Rare Skin Reaction Reported With Tirzepatide

A single case report described possible lichen planus pigmentosus inversus following tirzepatide initiation.

Conexiant

April 28, 2026

FDA Clears Self-Administered Lupus Therapy

Once-weekly autoinjector approval was based on Phase 3 data, with safety consistent with intravenous administration.

Conexiant

April 28, 2026

Cutaneous Rhabdomyosarcoma May Mask Melanoma

Molecular and epigenetic profiling suggested most tumors in a rare cutaneous sarcoma cohort were better classified as transdifferentiated melanoma.

Conexiant